MANHASSET, NY – The leaders of North Shore University Hospital‘s (NSUH) Neurocritical Care Center team, were recognized for their dedication and diligent work in this year’s enrollment in the CLEAR III clinical trial, funded by the National Institutes of Health (NIH). David LeDoux, MD, director of neurocritical care at NSUH and principal investigator of the NSUH-based CLEAR III clinical trial, and Oleg Rivkin RPA-C, supervising physician assistant and the study’s coordinator, are working in collaboration with Johns Hopkins University School of Medicine, the primary sponsor for the study.
CLEAR III is a 500-patient, Phase-III, randomized, international clinical trial that is using a select dose of a tissue plasminogen activator (Activase) to quickly remove blood from the ventricles of the brain in patients presenting with an intraventricular hemorrhage (IVH). The main objective is to prevent brain injury and improve clinical outcomes. NSUH is one of more than 70 academic medical centers participating in the study, which is looking at whether this therapy can reduce mortality and improve the quality of life for patients who have suffered an IVH. If successful, it could significantly change the way IVH is treated around the world.
Mr. Rivkin, RPA-C, was awarded the coordinator bronze medal in the CLEAR III 2011-2012 ThrombOlympics performance contest, for his involvement in making NSUH the second-highest enroller in the study.
“It is a privilege to work with a dedicated team of neurosurgeons, physician assistants and nurses who have helped us achieve this recognition,” said Dr. LeDoux. “I believe this treatment will be a major breakthrough in the management of those brain injury patients, for whom the mortality rate is now 40-60 percent. We are excited and motivated to increase our enrollment with the help of our colleagues at North Shore University Hospital and those at other institutions.”
About North Shore University Hospital’s Neurocritical Care Center
The Neurocritical Care Center at North Shore-LIJ Health System's Cushing Neuroscience Institute features a 16-bed intensive care unit (ICU) that was established in 2007. Every month, the center sees 110-130 patients, providing expert care via a team approach to the management of patients with subarachnoid hemorrhage, traumatic brain injury, intracerebral hemorrhage, complicated stroke and other disorders. Through the hospital system’s transfer center, the neurocritical ICU staff provides support to over 1,200 patients each year on Long Island and the surrounding boroughs who are afflicted with brain or spinal cord injury.
The Neurocritical Care Center uses state-of-the-art technology such as intracranial pressure monitoring, brain oxygen monitoring and current ultrasound techniques to provide critically ill patients with the highest quality specialty care services. In addition, the neurocritical ICU staff is actively involved in international and domestic research trials.
A dedicated unit that provides 24-7 intensivist coverage for critically ill patients, the Neurocritical Care Center provides comprehensive care through detailed, daily teaching rounds which include nurses, residents, fellows and a multidisciplinary team of physical and occupational therapists, respiratory therapists, nutritionists and social workers. Patients are treated through multi-modality monitoring, depending on the severity of their neurologic injury. A portable CAT scan is housed in the neurosurgical ICU for patients needing emergent imaging.
For more information about NSUH’s Neurocritical Care Center visit, http://www.northshorelij.com/cushing-neuroscience-institute/our-centers/neurocritical-care-center-overview.